Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Category 2

Growth Hormone (2)

First-year Growth Response to GH in Relation to Final Height Outcome in Prepubertal Children with Idiopathic GH Deficiency
aDepartment of Pediatric Endocrinology, University Hospital Maastricht, Maastricht, The Netherlands; bDepartment of Pediatric Endocrinology, University Hospital Antwerp, Antwerp, Belgium; cThe Belgian Study Group for Pediatric Endocrinology, Brussels, Belgium; dDepartment of Pediatric Endocrinology, University Children’s Hospital HUDE, Brussels, Belgium; eDepartment of Pediatric Endocrinology, University Hospital Brussels, Brussels, Belgium; fDepartment of Pediatric Endocrinology, University Hospital Ghent, Ghent, Belgium
Reevaluation of GH Secretion During Puberty in Children Diagnosed as GH-deficient During Childhood
Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, ‘Giambattista Rossi’ Hospital, University of Verona, Verona, Italy
Long-Term Effects of GH Replacement Therapy on Thyroid Function in GH Deficiency Children
Pediatric Endocrinology Unit, Department of Translational Medical Sciences, University ‘Federico II’ of Naples, Naples, Italy
GH Dosing Patterns in Short Children Born Small for Gestational Age
aHôpital des Enfants, Toulouse, France; bInstitute for Experimental Paediatric Endocrinology, Charité – Universitätsmedizin Berlin, Berlin, Germany; cSchool of Medicine, Belgrade University, Belgrade, Serbia; dInstitute for Mother and Child Health Care of Serbia, Belgrade, Serbia; eNovo Nordisk A/S, Søborg, Denmark; fNovo Nordisk Health Care AG, Zurich, Switzerland
Two-Year Data from a Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human GH, in Short Children Born Small for Gestational Age
aUniversity Children’s Hospital Munich, Munich, Germany; bMedical University, Gdansk, Poland; cChildren’s Health Research Institute, Warsaw, Poland; dPomeranian Medical University, Szczecin, Poland; eUniversity of Medicine and Pharmacy ‘Gr.T.Popa’, Iasi, Romania; fTblisi State Medical University, Tblisi, Georgia; gSandoz Biopharmaceuticals, Holzkirchen, Germany
Effects of Gender and Gestational Age on GH Treatment in Very Young Children Born Small for Gestational Age
aFederal University of Parana, Curitiba, Brazil; bPfizer, Inc., Endocrine Care, Sollentuna, Sweden; cPfizer, Inc., Endocrine Care, Berlin, Germany
Two-Year Results from Patro Children, a Multi-Centre, Non-Interventional Study of the Long-Term Efficacy and Safety of Omnitrope® in Children Requiring GH Treatment
aDepartment of Paediatric Endocrinology, University of Leipzig Medical School, Leipzig, Germany; bDepartment of Paediatrics, Royal Alexandra Children’s Hospital, Brighton, UK; cDepartment of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital, Stockholm, Sweden; dDepartment of Clinical Science/Paediatrics, Umeå University, Umeå, Sweden; eSandoz International GmbH, Holzkirchen, Germany; fDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, Llubljana, Slovenia; g25 Rue Boudet, Bordeaux, France
The Effect of Two Different GH Dosages on Final Height and Bone Geometry
aOspedale Regionale, Bolzano, Italy; bUniversità di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; cOspedale Carlo Poma, Mantova, Italy; dSpedali Civili, Brescia, Italy
Baseline Body Composition of Children with Short Stature Diagnosed for GH Deficiency
aDepartment of Pediatrics, Pediatric Endocrinology and Diabetes, Medical University of Silesia, Katowice, Poland; bScientific Society of Medical Students, Medical University of Silesia, Katowice, Poland
Efficacy, Adherence, and Cost Study According to Pathology and Treatment Devices in Children Treated with GHRH
aChildren’s Endocrinology Section, Pediatric Service, Vitoria/Basque Country, Spain; bPharmacy Service, University Hospital of Alava, Vitoria/Basque Country, Spain